Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.40%
#4 aPriori aPriori +133.73%
#5 Bedrock Bedrock +69.96%
#6 Cysic Cysic +48.18%
#7 Prom Prom +40.32%
#8 Playnance Playnance +34.95%
#9 COTI COTI +27.64%
#10 Bitway Bitway +26.68%
Coin of the day
Wrapped One Wrapped One
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rang in Aktien #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aktienkurs
$0.00023723
Zuletzt synchronisiert: 2024-08-26
Marktkapitalisierung
$1.41K
Veränderung (1 Tag)
111.67%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Kategorie

Healthcare
Gewinn für Pharnext S.A. (ALPHA)
Gewinn im Dec 2023 TTM: $-31.69M
Laut den aktuellen Finanzberichten von Pharnext S.A. betragen die aktuellen Gewinne des Unternehmens $-31.69M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-43.29M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2021, der $-38.48M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Pharnext S.A. von 2013 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -16,747.05%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -6,256.06%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -9,585.74%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR